Logo

23andMe's MAP Report Receives FDA's 510(k) Clearance for Hereditary Colorectal Cancers

Share this
23andMe's MAP Report Receives FDA's 510(k) Clearance for Hereditary Colorectal Cancers

Tuba Khan

23andMe's MAP Report Receives FDA's 510(k) Clearance for Hereditary Colorectal Cancers

  Shots:
  • MAP Report is a direct-to-consumer genetic test and has received FDA approval for MUTYH-associated polyposis (MAP)- a hereditary colorectal cancer syndrome
  • Post-FDA approval for BRCA1/BRCA2 (Selected Variants) Genetic Health Risk report in Mar 2018- 23andMe has received its second FDA approval for MAP Report detecting two variants in people with MAP
  • The approval allows patients for genetic testing with accurate results & is available for patients with educational module choosing to view their MAP report
Click here to read full press release/ article | Ref: 23andMe | Image: Twitter

Click Here

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family